Chinese Academy of Sciences

Mitsubishi Tanabe Pharma Corporation

Shanghai Pharmaceuticals Holding Co., Ltd.

Fudan University

Topharman Shanghai Co., Ltd.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Shanghai Miracogen Inc

Zhejiang University

Shanghai Haihe Pharmaceutical Co., Ltd.

Topharman Shandong Co., Ltd.

Mabwell (shanghai) Bioscience Co., Ltd.

Jiangsu Mabwell Health Pharmaceutical R&d Co., Ltd.

Shanghai Lead Discovery Pharmaceuticals Limited Company

Shanghai Pharmaceuticals Holdings Co., Ltd.

Mabwell Bioscience Co., Ltd.

Jingkang Shen

Tao Meng

Lanping Ma

Xin Wang

Guangxin Xia

Toru Iijima

Ke Yu

Hiroshi Sugama

Bing Xiong

Wei Zhang

Takayuki Kawaguchi

Ting Yu

Jianshu Xie

Miki Hirai

Hualiang Jiang

Meiyu Geng

Jingshan Shen

Yi Jing Zhu

Jianfeng Li

Xia Peng

Yoichi Takahashi

Xuesai Zhang

Qingrou Li

Yongliang Zhang

Qing Lin

Jing Lan Chen

Zheng Liu

Jing Jing Zhang

Jian Ding

Qi Rong Wang

Jia Tao Li

Hong Tao Liu

Ying Chu Wang

Zhen Wang

Fei Ye

Kaixian Chen

Tao Sun

Jianping Zuo

Hidenori Akatsuka

Guanghui Tian

Jing Ai

Jianhua Shen

Zehong Miao

Rongxia Zhang

Xiaojun Yang

Yu Hao

Hongli Peng

Jinfeng Zhang

Ying Wang

Yinchun Ji

Danqi Chen

Zhiyan Du

Nobumasa Awai

Xiaomin Luo

Xu Shen

Xican Tang

Huixin Wan

Lili Chen

Yi Zang

Shanshan Song

Weiliang Zhu

Jianping Hu

Donglu Bai

Yiming Yang

Haibin Luo

Cheng Zhu

Qian Tan

Dayuan Zhu

Yi Zhu

Rui Jin

Xuejun Liu

Yongping Yu

Wenteng Chen

Qing Jin

Aixiang Liu

Xinjian Chen

Guozhang Jin

Tiema Yan

Yanjun Pan

Chunshan Gui

Yifu Yang

Xianhan Zhuang

Xuchang He

Yingqing Wang

Ying Dong

Kazuhiro Tanaka

Takuji Yamaguchi

Shanhao Jiang

Guansong Wu

Jinlai Lin

Takeshi Wakamatsu

Jing Al

Hiroaki Nishimura

Yuchi Ma

Yuelei Chen

Arie Zask

Jinpeng Pei

Lanfang Meng

Yiyi Chen

Yuko Togashi

A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.

Tissue factor-targeted antibody-drug conjugate

Disclosed are a new AXL-targeting monoclonal antibody and antibody-drug conjugate. Also disclosed is a method for preparing said antibody and antibody-drug conjugate. The AXL antibody of the present invention can bind with purified human AXL protein and multiple AXL on tumor cell surface with high effectiveness and high specificity. Said humanized antibody also has high affinity and low immunogenicity. Said AXL antibody-drug conjugate has markable performance against tumors having high AXL expression.

AXL-targeting antibody, antibody-drug conjugate, preparation method therefor, and use thereof

The present disclosure relates to a fused ring pyrimidine amino compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically disclosed in the present disclosure are the compound shown in formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof, a metabolite thereof, a metabolic precursor thereof, or a prodrug thereof. The fused ring pyrimidine amino compound of the present application has good inhibitory activity against DDRs, particularly DDR2, and has a good therapeutic effect on tumors and fibrotic diseases, especially pulmonary inflammation and pulmonary fibrosis. Also disclosed in the present disclosure are a preparation method for the compound shown in formula I, and a use thereof. 

Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof

The present invention relates to dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof. The inhibitor of the present invention is compound represented by general formula (I), or stereoisomer, pharmaceutically acceptable salt, prodrug, solvate, hydrate and crystal form thereof. The definition of each substituent is as described in the description and claims. The compound represented by general formula (I) of the present invention may inhibit bromodomain recognition protein and may be used for preparing medicament which regulates the apparent state of cells and treats series of diseases and symptoms which are mediated by the bromodomain recognition protein. 

Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof

Provided in the present invention are a di-substituted maleic amide linker conjugated to an antibody and a preparation method and use thereof. In particular, the present invention conjugates a strongly cytotoxic active substance to a biomacromolecule through a class of new linkers. The class of linkers can selectively act simultaneously with disulphide chains, so as to greatly improve the substance homogeneity of a conjugate. The conjugate prepared by the linker of the present invention has a high inhibitory activity on a cell strain expressing the corresponding antigen. Also provided is a method for preparing the above-mentioned conjugate and the use.

Di-substituted maleic amide linker for antibody drug conjugating and preparation method and use thereof

Provided is a process of synthesizing a substituted pyridine and pyrimidine compound. Particularly, provided is a method for preparing a compound of formula III via a compound of formula II', wherein the definition of each of groups is as described as the description. Compound with other methods, the method in the present invention has features of high yield and a result product being easier to separate. 

Process of synthesizing substituted pyridine and pyrimidine compound

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein Ris a cycloalkyl group and the like, Ris an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is &#x2014;O&#x2014; and the like, and Rto Rare the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.

Nitrogen-containing saturated heterocyclic compound

This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of producing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and/or treating diseases and tumors associated with abnormal protein tyrosine kinase. 

Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof

The present invention belongs to the field of pharmaceutical Chemistry. In particular, the present invention relates to a pyridopyrimidine or pyrimidopyrimidine compound as represented by general formula (I), or an isomer thereof or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, a preparation method, a pharmaceutical composition and uses thereof in preparing a mTOR inhibitor. As a mTOR inhibitor, the compound or the pharmaceutical composition thereof can be used for treating a disease or condition due to PI3K-AKT-mTOR signalling pathway malfunction. 

Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutical composition, and use thereof

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor. wherein Ris a cycloalkyl group or an alkyl,

Renin inhibitor

Disclosed are as represented by Formula (I) a quinazoline derivative and a pharmaceutical acceptable salt thereof, or, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug of both. Also disclosed are a preparation method therefor, an intermediate, a pharmaceutical composition having the quinazoline derivative, and an application thereof. The quinazoline derivative of the present invention is provided with improved anti-tumor activity. 

Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein Ris a cycloalkyl group and the like, Ris an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is &#x2014;O&#x2014; and the like, and Rto Rare the same or different and a hydrogen atom and the like;or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.

The present invention provides a morpholine derivative of the formula [I]; wherein Ris a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, a cycloalkyl group or an alkyl group; Ris a substituted alkyl group, an optionally substituted aryl group, an optionally substituted heterocyclo group, an optionally substituted alkylcarbonyl group, an optionally substituted arylcarbonyl group, an optionally substituted heterocyclo-substituted carbonyl group or a cycloalkylcarbonyl group; T is a methylene group or a carbonyl group; R, R, Rand Rare the same or different and a hydrogen atom, an optionally substituted carbamoyl group or an optionally substituted alkyl group;or pharmaceutically acceptable salts thereof. These compounds are useful as a renin inhibitor.

Morpholine derivative

The present invention relates to a class of phenylpyrimidone compounds, the pharmaceutical composition, the preparation method and the use thereof. More specifically, the present invention relates to a type of phenylpyrimidone compounds of the following formula I, the pharmaceutically acceptable salts or solvates thereof and to the pharmaceutical composition as well as the preparation method of the compounds. The compounds of formula I according to the present invention can effectively inhibit type V phosphodiesterase (PDE5), and thus can be used for the treatment of various vascular disorders, such as male erectile dysfunction, pulmonary hypertension and the like. 

Phenylpyrimidone compounds, the pharmaceutical compositions, preparation methods and uses thereof

Growing community of inventors

Shanghai, China

Jingkang Shen